Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
Max M. Wattenberg(Washington University in St. Louis), Kim A. Reiss(University of Pennsylvania), Gregory L. Beatty(Cancer Research Institute), Shun Yu(University of Pennsylvania), Peter J. O’Dwyer(University of Pennsylvania), Evan S. Siegelman(University of Pennsylvania), Susan M. Domchek(University City Science Center), Katherine L. Nathanson(Translational Therapeutics (United States)), Mark Rosen(California University of Pennsylvania), Daniella Asch(University of Pennsylvania)
Cited by 206
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k